Biogen Idec
10 Cambridge Center
Cambridge MA 02142 United States
Phone:
Biogen Idec is a global biotechnology leader focused on delivering crucial medicines that address unmet medical needs in Neurology, Oncology, Immunology, Cardiology and emerging therapeutic areas. With over 4,700 employees worldwide, we excel in all areas
of drug development and distribution — from R&D to manufacturing and marketing — and saw our revenues grow to over $4.3 billion during 2009.
The heart of our mission and growth strategy is our long-standing focus on biologics and small molecule therapies in the pursuit of life-altering and life-saving therapies.
Global Opportunities
Headquartered in Cambridge, Massachusetts, Biogen Idec has a global presence in more than 25 countries and distribution networks in 90 countries. Major facilities include:
- • Two centers of research excellence in the USA: Cambridge, Massachusetts, and San Diego, California
- • Three major manufacturing centers: Research Triangle Park, North Carolina; Cambridge, Massachusetts; and Hillerød, Denmark
- • World-class patient services center in Research Triangle Park, North Carolina
- • Additional offices in Canada, Australia, Japan and throughout Europe, including international headquarters in Zug, Switzerland
Products & Progress
Our currently marketed products include:
- • AVONEX®, the #1 prescribed therapeutic product for multiple sclerosis (MS)
- • RITUXAN®, the current standard of care for non-Hodgkin’s lymphoma, which has also been indicated for the treatment of moderate to severe rheumatoid arthritis
- • TYSABRI®, a breakthrough therapy for multiple sclerosis (MS)
We currently have more than 20 products in Phase 2 clinical trials and beyond.
|
Email: Visit.our.website@www.biogenidec.com
Ownership: Public
Website: Biogen Idec
Symbol: BIIB
Stock Exchange: NASDAQ
Industry: Biopharmaceutical
Segment: Biotechnology
|
|